Sensors,
Год журнала:
2022,
Номер
22(19), С. 7423 - 7423
Опубликована: Сен. 29, 2022
Coronavirus
disease
2019
(COVID-19)
is
a
highly
virulent
infection
that
has
caused
pandemic
since
2019.
Early
diagnosis
of
the
been
recognized
as
one
important
approaches
to
minimize
pathological
impact
and
spread
infection.
Point-of-care
tests
proved
be
substantial
analytical
tools,
especially
lateral
flow
immunoassays
(lateral
tests)
serve
purpose.
In
last
few
years,
biosensors
have
gained
popularity.
These
are
simple
but
sensitive
accurate
devices
composed
from
selective
molecule
such
an
antibody
or
antigen
sensor
platform.
Biosensors
would
advanced
alternative
current
point-of-care
for
COVID-19
standard
laboratory
methods
well.
Recent
discoveries
related
diagnostic
COVID-19,
development
specific
antibodies
virus
parts
their
genetic
information
reviewed.
Frontiers in Immunology,
Год журнала:
2024,
Номер
14
Опубликована: Янв. 3, 2024
In
this
review
article,
we
explore
the
characteristics
of
RNA
viruses
and
their
potential
threats
to
humanity.
We
also
provide
a
brief
overview
primary
contemporary
techniques
used
for
early
detection
such
viruses.
After
thoroughly
analyzing
strengths
limitations
these
methods,
highlight
importance
integrating
nucleic
acid
testing
with
immunological
assays
in
virus
detection.
Although
notable
methodological
differences
between
immune
pose
challenges,
emerging
single-molecule
immunoassay-digital
ELISA
may
be
applied
technically
integrate
techniques.
emphasize
that
greatest
value
digital
is
its
extensive
compatibility,
which
creates
numerous
opportunities
real-time,
large-scale
Furthermore,
describe
possible
developmental
trends
various
aspects,
as
reaction
carriers,
identification
elements,
signal
amplification,
data
reading,
thus
revealing
remarkable
future
The
COVID-19
pandemic
over
the
past
years
has
shown
a
great
need
for
rapid,
low-cost
and
on-site
detection
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2).
In
this
paper,
an
aptamer-based
colloidal
gold
nanoparticle
lateral
flow
test
strip
was
well
developed
to
realize
visual
wild
type
SARS-CoV-2
spike
protein
(SP)
multiple
variants.
Under
optimal
reaction
conditions,
low
limit
S
0.68
nM
acquired,
actual
recovery
83.3%
108.8%
real
world
samples.
This
suggests
potential
tool
prompt
with
good
sensitivity
accuracy,
new
method
development
alternative
antibody
strips
other
viral
targets.
